drugset / Trial / NCT01261156
A Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effects of diltiazem on the pharmacokinetics (PK) and pharmacodynamics (PD) of E5555 and its metabolites in healthy subjects.
Timeline
- Start
- 2010-10
- Primary completion
- 2010-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atopaxar | Small molecule | 100 mg | Oral |
| Subject | Atopaxar | Small molecule | 300 mg | Oral |
| Subject | Diltiazem | Small molecule | 360 mg | Oral |
Indications
No indication recorded.